Repositioning Candidate Details
| Candidate ID: | R1022 |
| Source ID: | DB06467 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Apolizumab |
| Synonyms: | Apolizumab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers. |
| CAS Number: | 267227-08-7 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Apolizumab is a humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
